NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TRDA

Entrada Therapeutics Inc

Jun 30 • 04:00PM ET

6.72

Dollar change -0.19
Percentage change -2.75	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA REGN PFE GILD BNTX NVAX VRTX SRPT INCY RNA

| Held by: VTI IWM VXF IWN IBB VTWO SCHA FDM VHT IWC

Scroll to Statements

Index	RUT	P/E	8.31	EPS (ttm)	0.81	Insider Own	41.48%	Shs Outstand	37.94M	Perf Week	-4.55%
Market Cap	255.05M	Forward P/E	-	EPS next Y	-4.25	Insider Trans	-0.01%	Shs Float	22.21M	Perf Month	-14.94%
Enterprise Value	-70.46M	PEG	-	EPS next Q	-0.85	Inst Own	52.90%	Short Float	4.96%	Perf Quarter	-29.71%
Income	24.78M	P/S	1.48	EPS this Y	-288.17%	Inst Trans	-2.08%	Short Ratio	7.28	Perf Half Y	-61.73%
Sales	172.22M	P/B	0.61	EPS next Y	-34.37%	ROA	4.97%	Short Interest	1.10M	Perf YTD	-61.13%
Book/sh	11.00	P/C	0.67	EPS next 5Y	-	ROE	7.22%	52W High	21.79 -69.16%	Perf Year	-52.34%
Cash/sh	10.08	P/FCF	-	EPS past 3/5Y	- -	ROIC	5.30%	52W Low	6.80 -1.18%	Perf 3Y	-28.89%
Dividend Est.	-	EV/EBITDA	-8.98	Sales past 3/5Y	- -	Gross Margin	97.83%	Volatility	3.65% 4.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-0.41	EPS Y/Y TTM	24.45%	Oper. Margin	2.39%	ATR (14)	0.38	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	21.88	Sales Y/Y TTM	5.74%	Profit Margin	14.39%	RSI (14)	30.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	21.88	EPS Q/Q	-162.54%	SMA20	-11.03%	Beta	-0.10	Target Price	20.50
Payout	0.00%	Debt/Eq	0.14	Sales Q/Q	-65.23%	SMA50	-16.40%	Rel Volume	1.06	Prev Close	6.91
Employees	183	LT Debt/Eq	0.12	Earnings	May 08 BMO	SMA200	-48.62%	Avg Volume	151.54K	Price	6.72
IPO	Oct 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	46.74% 102.12%	Trades		Volume	160,972	Change	-2.75%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
Jun-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.11%
May-29-25 11:10AM	Entradas Phase I/II trial of DMD treatment authorised to begin in EU (Clinical Trials Arena)
May-28-25 07:00AM	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
May-08-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.64%
07:00AM	Loading…
07:00AM	Entrada Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
Apr-29-25 10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks) -5.08%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-25-25 10:03AM	Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment (Clinical Trials Arena) -5.79%
Mar-24-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
Feb-27-25 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
06:11AM	Loading…
Feb-26-25 06:11AM	AstraZenecas next breast cancer drug; Madrigals accelerating MASH launch (BioPharma Dive)
Feb-25-25 01:05PM	FDA removes clinical hold on Entradas Duchenne therapy (Clinical Trials Arena) -5.68%
Feb-24-25 07:00AM	Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 (GlobeNewswire)
Feb-12-25 07:58AM	Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-04-25 07:19AM	Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment (Clinical Trials Arena)
Feb-03-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-30-25 04:05PM	Azenta Announces the Election of Dipal Doshi to its Board of Directors (PR Newswire)
Dec-18-24 07:00AM	Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.32%
Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
07:00AM	Loading…
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%
Dec-22-22 08:07AM	Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More (Zacks) -5.30%
Dec-20-22 10:03AM	Entrada (TRDA) Down on Regulatory Update for DMD Candidate (Zacks) -19.76%
Dec-19-22 04:30PM	Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -6.09%
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-09-22 01:41PM	Entrada (TRDA) Surges on Collaboration With Vertex for DMI (Zacks) -9.19%
Dec-08-22 04:12PM	Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy (Investor's Business Daily) +18.51%
10:58AM	Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder (Benzinga)
08:24AM	Entrada Therapeutics shares jump on collaboration with Vertex (MarketWatch)
07:00AM	Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) (Business Wire)
Nov-22-22 07:00AM	Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-07-22 07:00AM	Entrada Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -10.02%
Aug-30-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 07:00AM	Entrada Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 07:00AM	Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-19-22 07:00AM	Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer (GlobeNewswire) +8.81%
Jul-14-22 10:47AM	We're Hopeful That Entrada Therapeutics (NASDAQ:TRDA) Will Use Its Cash Wisely (Simply Wall St.)
Jul-06-22 07:00AM	Entrada Therapeutics to Present at William Blair Biotech Focus Conference (GlobeNewswire)
Jun-01-22 07:00AM	Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference (GlobeNewswire) -15.24%

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding a pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
5AM Opportunities I, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	19,265	133,121		Jun 27 05:05 PM
5AM Ventures V, L.P.	Director	Jun 27 '25	Proposed Sale	6.91	55,735	385,129		Jun 27 05:03 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Apr 03 '25	Option Exercise	2.10	11,134	23,381	120,670	Apr 04 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 17 '25	Sale	10.67	1,784	19,035	109,536	Mar 19 04:32 PM
KORY WENTWORTH	Officer	Mar 17 '25	Proposed Sale	10.81	1,784	19,285		Mar 17 04:32 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Option Exercise	2.10	5,000	10,500	78,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Option Exercise	2.10	1,000	2,100	74,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Sale	20.00	5,000	99,978	73,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Sale	19.97	1,000	19,970	73,849	Dec 03 05:26 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 03 '24	Sale	20.15	11,703	235,786	144,997	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 02 '24	Sale	20.26	4,088	82,834	156,700	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 29 '24	Sale	20.00	100	2,000	160,788	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 13 '24	Sale	20.04	2,700	54,109	160,888	Nov 13 04:49 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 11 '24	Sale	20.01	1,409	28,191	163,588	Nov 13 04:49 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Option Exercise	2.10	6,000	12,600	82,486	Nov 13 04:47 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Sale	19.98	8,637	172,562	73,849	Nov 13 04:47 PM
NATARAJAN SETHURAMAN	Officer	Nov 11 '24	Proposed Sale	19.82	18,762	371,863		Nov 12 07:54 AM
KORY WENTWORTH	Officer	Nov 11 '24	Proposed Sale	19.82	14,637	290,105		Nov 12 07:53 AM
Sethuraman Natarajan	President, Research & Develop.	Nov 06 '24	Sale	18.85	12,299	231,776	164,997	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 05 '24	Sale	18.18	5,171	94,006	177,296	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 04 '24	Sale	18.02	749	13,498	182,467	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Oct 16 '24	Sale	18.00	600	10,800	183,216	Oct 18 04:31 PM
NATARAJAN SETHURAMAN	Officer	Oct 16 '24	Proposed Sale	17.53	20,057	351,599		Oct 16 04:25 PM
Dowden Nathan J	President & COO	Sep 26 '24	Sale	16.00	847	13,552	125,149	Sep 30 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Sep 09 '24	Sale	14.97	3,195	47,832	76,486	Sep 10 04:34 PM
Dowden Nathan J	President & COO	Sep 09 '24	Sale	15.07	1,904	28,690	125,996	Sep 10 04:33 PM
Dowden Nathan J	President & COO	Sep 06 '24	Sale	15.19	399	6,063	127,900	Sep 10 04:33 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 09 '24	Sale	15.09	2,642	39,862	183,816	Sep 10 04:32 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 06 '24	Sale	15.24	600	9,141	186,458	Sep 10 04:32 PM
KORY WENTWORTH	Officer	Sep 09 '24	Proposed Sale	14.80	3,195	47,286		Sep 09 04:27 PM
NATHAN DOWDEN	Officer	Sep 06 '24	Proposed Sale	15.39	3,150	48,478		Sep 06 04:19 PM
Dowden Nathan J	President & COO	Aug 16 '24	Option Exercise	1.74	20,000	34,800	157,204	Aug 20 04:33 PM
Dowden Nathan J	President & COO	Aug 16 '24	Sale	16.27	27,097	440,801	130,107	Aug 20 04:33 PM
NATHAN DOWDEN	Officer	Aug 16 '24	Proposed Sale	16.26	27,097	440,597		Aug 16 04:25 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 15 '24	Sale	18.00	638	11,484	188,814	Jul 16 04:43 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 12 '24	Sale	18.00	600	10,800	189,452	Jul 16 04:43 PM
Doshi Dipal	CEO	Jul 15 '24	Sale	17.81	1,600	28,497	334,475	Jul 16 04:42 PM
Doshi Dipal	CEO	Jul 12 '24	Sale	18.00	300	5,400	336,075	Jul 16 04:42 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 08 '24	Sale	14.95	1,758	26,282	81,412	Jul 10 04:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TRDA

Entrada Therapeutics Inc

Upgrade your FINVIZ experience